Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

on compared to $2.67 billion for the twelve months ended Dec. 31, 2007. The prior year included only one quarter of contribution from the former Merck Generics business. In calendar year 2008, the former Merck Generics business contributed revenues of $2.57 billion. Also included in total revenues for the current year is $468.1 million of deferred revenue recognized related to the sale of our rights of Bystolic.

Excluding revenue contributed by the former Merck Generics business for both years, and the Bystolic revenue in the current year, total sales for calendar year 2008 were $2.10 billion compared to $1.97 billion.

For calendar year 2008, Generics reported total revenues of $3.91 billion compared to $2.22 billion in calendar year 2007. Total revenues from North America were $1.85 billion for calendar year 2008 compared to $1.68 billion for calendar year 2007, representing an increase of $176.6 million. Excluding revenue contributed from the acquisition of the former Merck Generics business from both periods, total North America revenues increased by $99.8 million or 6.2%. This increase is the result of new product revenue and favorable volume, partially offset by unfavorable pricing. Products launched during calendar year 2008 contributed revenues of $264.0 million, with paroxetine extended-release and levetiracetam accounting for the majority.

Total calendar year 2008 third-party revenues for EMEA, Asia Pacific and Specialty were $1.52 billion, $537.4 million and $386.0 million, respectively. Matrix reported total revenues of $444.8 million, of which $376.0 million represented third-party sales, compared to total revenues of $389.6 million for calendar year 2007, of which $343.6 million represented third-party sales.

Gross profit for calendar year 2008 was $2.07 billion and gross margins were 40.3%. For calendar year 2007, gross profit was $1.11 billion and gross margins were 41.6%. Exc
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced its results ... fiscal 2014 year-end financial statements and MD&A have been filed on SEDAR ... , 2014 , 2013 Revenue 3,968 , ... 1,326 , 1,703 , 2,231 , ... 3,377 , 4,562 Ebitda* 92 , 418 ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
(Date:4/29/2015)... 2015 The leading Regenerative Veterinary Medicine ... regenerative stem cell therapy has processed more than 11,000 ... discover a successful treatment for horses with potentially fatal ... signed a worldwide exclusive license for adipose-derived (fat derived) ... horse was treated in January 2004. Shortly after, the ...
(Date:4/29/2015)... - Northern Biologics Inc., a privately held biotechnology company ... strategic collaboration with Celgene Corporation.  As part of ... upfront cash payment. It will use the funds ... will have the right to receive additional future ... Under the agreement, Northern Biologics ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Robotics today announced,that the European Union (EU) ... results of the SafeChemo Project it sponsored ... objectives were to scientifically and,independently establish if ... system for the safe preparation of hazardous ...
... Jan. 5 Baxter,International Inc. and Halozyme Therapeutics, ... start of a Phase III clinical trial of ... as KIOVIG in the European,Union, with Halozyme,s recombinant ... of primary immunodeficiency (PID).,The purpose of this clinical ...
... BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... Pharmaceutical Co., Ltd., has been granted high tech,status ... is awarded by the PRC to,recognize companies that ... revenues generated by their own proprietary patented or,innovative ...
Cached Biology Technology:Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 2Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 3Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 2Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 3Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 5BMP Sunstone Receives High Tech Status 2BMP Sunstone Receives High Tech Status 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/18/2015)... , March 18, 2015 As mobile ... new revolutionary smart wallets and apps continue to be introduced ... entrenched in the mobile payment industry in focus today are:  ... Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... Park, MD (July 27, 2010) -- Drug delivery inside ... a maze of aqueous solutions, lipid membranes, and barriers ... reported in the American Institute of Physics publication the ... model that accurately predicts the hydration free energy (HFE) ...
... Park, MD (July 27, 2010) -- Fluids experts writing ... is published by the American Institute of Physics, are ... accurately probe the properties of turbulence near walls. High-Reynolds-number ... in aeronautics, naval applications, energy conversion processes, manufacturing, mixing ...
... fish scientist has received the Robert H. Gibbs, Jr. ... knowledge of fish diversity. The honor to Dr. ... the Ichthyology Department, was announced earlier this month in ... Society of Ichthyologists and Herpetologists. The Gibbs award is ...
Cached Biology News:
...
...
... Zero Blunt TOPO PCR Cloning Kit ... for high-efficiency (>=95%) cloning of blunt-end ... polymerases. The kit includes the linearized ... for 5-minute bench-top ligations without ligase ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: